Skip to main content

Table 3 Incidence of worst NCI-CTCAE hematology grades during and up to 28 days after the end of study treatment (all-treated population)

From: A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

  Placebo + dacarbazine
(n = 38)
Bosentan + dacarbazine
(n = 38)
  Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin, n (%) 26 (68.4) 2 (5.3) - - 19 (50.0) 9 (23.7) 1 (2.6) 1 (2.6)
Leukocytes, n (%) 8 (21.1) 6 (15.8) 2 (5.3) - 10 (26.3) 7 (18.4) 1 (2.6) -
Neutrophils, n (%) 4 (10.5) 5 (13.2) 2 (5.3) 1 (2.6) 3 (7.9) 8 (21.1) 1 (2.6) -
Platelets, n (%) 11 (28.9) 3 (7.9) - - 10 (26.3) 3 (7.9) 2 (5.3) -